Nootropics Depot CEO Proposes New Reishi Standardization Paradigm

Nootropics Depot has released a white paper penned by CEO Paul Eftang advocating for a novel standardization paradigm for Reishi mushroom product quality. The publication challenges conventional marker-based assessment, proposing a system centered on groups of bioactive compounds.

Eftang argues that current Reishi quality standards, often relying on specific markers, do not fully represent the extract's bioactive profile. The white paper introduces the "Standardized Target Analyte Grouping" (STAG) framework, which aims to evaluate Reishi products based on holistic groupings of bioactive compounds rather than isolated markers.

The paper highlights that Reishi contains multiple compound classes with different pharmacological relevance. Commercial claims often focus on easily measured or familiar components, creating a gap between product claims and actual benefits. The proposed framework encourages industry stakeholders to develop more scientifically coherent and transparent quality standards.

The release continues Nootropics Depot's trend of technical publishing that critically examines industry standards, similar to their prior white paper on electrolytes. This work applies the same principle to mushroom quality, emphasizing the measurement of compounds most relevant to the product's intended function.